Stories
Addressing unmet medical needs through a breadth of targeted therapeutics
David has over thirty years of industry experience, where he held various global executive leadership positions in large pharmaceutical and commercial-stage biotechnology companies focused on oncology.
More Stories
hroughout my career, I’ve aspired to improve the lives of patients and their loved ones. At Mirati, our core values include accountability, empathy and collaboration, which I believe, when applied to science and medical innovation, have the potential to transform the targeted oncology space. I’ve seen firsthand the impact of the Mirati team embracing and applying these elements through our work.
Addressing unmet needs in the oncology space can be challenging, but our team of scientists embraces the challenge with persistence and commitment. For many of us, this commitment has been intrinsically motivated by walking alongside a loved one’s cancer journey. With 1.9 million new cancer diagnoses expected in the US this year1, there is a huge need and significant potential to impact a large population through a wide range of targeted therapeutics. I’m confident the experience, knowledge and commitment of our team can have a meaningful impact to improve the lives of those living with cancer.
With 1.9 million new cancer diagnoses expected in the US this year1, there is a huge need and significant potential to impact a large population through a wide range of targeted therapeutics.
Our cutting-edge scientific innovation, combined with our dedication to improving patients’ lives, has allowed us to deepen our pipeline of targeted oncology therapies. By investigating the genetic and immunological drivers of cancer, we are seeing great opportunities to create meaningful impact with our late-stage and near-launch programs. The positive results seen recently in two groups of patients – those with previously treated NSCLC harboring a KRASG12C mutation and patients with KRASG12C-mutated NSCLC with active and untreated CNS metastases – highlight Mirati’s potential to positively impact patients living with cancer. Recent data presented at the European Society for Medial Oncology Congress 2022 points to our dedication to developing safe treatment options for other solid tumors, including colorectal cancer, that improve upon the standard of care as well.
With Mirati’s discovery programs, we are also developing and exploring the applications of other therapies, like our MTA-cooperative PRMT5, SOS1 and next-generation KRAS inhibitors. These treatments have the potential to be transformative for a wide range of cancer patients, and I’m eager to see these programs continue to advance.
As we approach the end of the year, I’m proud of the progress Mirati has made toward delivering innovative cancer treatment options. And, I’m especially excited about our potential to create medicines that can impact cancer across mutation and tumor types, and even complement other agents in our pipeline to create greater impact. We have established our marketing strategy, market access, patient support and medical affairs capabilities, and now, we have in place all the components necessary to successfully deliver this innovation to the patients in need.
I’m excited at the future for Mirati and what it holds for patients and their loved ones, and I’m grateful to our team for their relentless pursuit to make a difference for people living with cancer.